CompanyAVIRNasdaqBoston, MA

Atea Pharmaceuticals, Inc.

Atea develops oral antiviral therapies using a nucleos(t)ide prodrug platform targeting ssRNA viruses.

SEC EDGAR ClinicalTrials.gov ateapharma.com

10-QAug 12Latest SEC filing, period to Jun 30

Aug 12Latest story

August 2026

Atea reports Q2 2026 results, cites C-BEYOND Phase 3 win in hepatitis C

Aug 12Quarterly updateAtea Pharmaceuticals, Inc.

July 2026

Atea registers Phase 1 first-in-human trial of AT-587 for hepatitis E

Jul 27Trial updateAT-587 Atea Pharmaceuticals, Inc.